FDA Brief

Warning letters Drugs

FDA warning letter to

Skin Beauty Solutions

High riskIssued Jul 25, 2024Posted Jul 30, 2024Center for Drug Evaluation and Research (CDER)

FDA warns Skin Beauty Solutions that its chemical peel products are unapproved new drugs sold with acne and scar treatment claims.

What happened

FDA reviewed the company website in April 2024 and found it offered numerous chemical peel products, including multiple strengths of lactic acid, glycolic acid, combination glycolic and lactic acid, and salicylic acid. The website claims these products clear acne and scars, remove blackheads, remove dead skin cells, and treat dermatitis. FDA says the products are unapproved new drugs and notes adverse event reports of skin injuries from potent chemical peels, including burns, wounds, pain, swelling, and scarring.

What FDA found

  1. FDA says the chemical peels are drugs because the website claims they treat acne, scars, and dermatitis and affect the skin.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  2. FDA says the products are new drugs because they are not generally recognized as safe and effective for the claimed uses.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  3. FDA says the products are sold without an FDA-approved drug application.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)

What FDA wants

FDA asks the company to notify it in writing within fifteen working days of receipt of the letter about specific steps taken to address the violations, including steps to prevent recurrence and copies of related documentation. If corrective actions cannot be completed in that time, the company must state the reason for delay and the time within which it will do so; if it believes the products are not in violation, it must include reasoning and supporting information.

Who should pay attention

  • online sellers of cosmetic chemical peels
  • brands marketing exfoliating acids with acne or dermatitis claims
  • estheticians and consumers using high-strength chemical peels

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk